drugset / Trial / NCT01213836

Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia

NCT01213836

Phase 4 Completed 75 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindTreatment

Summary

This will be a phase IV 20 -32 day prospective, double blind, double-dummy, randomised crossover study that will evaluate the effect of quetiapine XR and quetiapine IR on cognitive performance in patients with schizophrenia stabilized on a single antipsychotic medication.

Timeline

Start
2010-11
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 400 mg
Comparator Quetiapine Small molecule 700 mg

Indications